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Introduction
Cardiovascular diseases (CVD) are leading causes of death worldwide.1–3 $ ¿[HGGRVH FRPELQDWLRQ RI HVWDEOLVKHG
drugs (polypill) was suggested as an effective strategy for 
controlling CVD.4 This approach may reduce costs of treatment 
and increase participants’ adherence and consequently will reduce 
CVD incidence and mortality. Regarding the high rates of CVD 
mortality in Golestan Cohort Study (GCS),5 it was suggested to 
consider the polypill strategy for primary and secondary 
prevention of CVD in this population. The GCS is a prospective 
population-based long-term study with 50,000 participants which 
started 10 years ago, primarily to study esophageal cancer which 
was exceptionally common in Northeastern Iran (eastern part of 
the Golestan province) with 99% follow-up success rate. CVD 
was found to be the etiology of death in 50% of all mortalities 
among GCS participants. The results of the pilot phase of polypill 
study suggested that it is feasible and even necessary to conduct a 
large-scale trial on GCS population.6 Therefore, the main phase of 
polypill study, called “PolyIran study”, was designed. The 
PolyIran study is a pragmatic cohort multiple cluster randomized 
WULDOFP5&7WRDVVHVVWKHVDIHW\DQGHI¿FDF\RIDVLQJOH¿[HG
dose combination of cardiovascular medications intervention for 
primary and secondary prevention of major cardiovascular events 
in middle-aged and elderly Iranians. The details of the PolyIran 
study have been described elsewhere.7 The enrolment phase 
started in February 2011 and was completed by April 2013, with 
each village considered a cluster. The follow-up phase of the 
PolyIran project began in May 2011. The intervention arm clusters 
were followed up at months 1, 2, 3, 6, and then at 6-month intervals 
whereas the control arm clusters were followed up at months 3, 6, 
and subsequently at 6-month intervals.
During follow-up visits, different types of information were 
collected including participants’ demographic data, pill counts, 
reasons for non-adherence, blood pressure measurement, new 
medications, symptoms, referrals and cardiovascular events. The 
full list of information collected in PolyIran follow-up visits is 
shown in Table 1.
Quality assurance and quality control constitute an important 
part of any clinical trial.8,9 Because of the importance and pivotal 
role of follow-up visits in the PolyIran study, the PolyIran Quality 
Control Program (PIQCP) was developed to assess the quality of 
data collection during PolyIran follow-up visits. It contained two 
questionnaires, one for the intervention group, and the other for 
Abstract
Background:7KH3RO\,UDQVWXG\LVDODUJHVFDOHSUDJPDWLFFOXVWHUUDQGRPL]HGFRQWUROOHGWULDORI¿[HGGRVHFRPELQDWLRQWKHUDS\3RO\SLOO
for prevention of cardiovascular diseases (CVD) in Iran. The PolyIran Quality Control Program (PIQCP) including a new questionnaire was 
developed to assess the quality of data collection during follow-up visits. The aim of this study was to assess the inter-rater reliability of 
PIQCP questionnaire.
Methods: The study was conducted in 26 (11%) randomly selected clusters (from a total of 236 PolyIran clusters). All participants within 
these 26 clusters were enrolled. The quality scores were measured according to the PIQCP guidelines by two independent raters. The 
LQWUDFODVVFRUUHODWLRQFRHI¿FLHQWV,&&ZHUHPHDVXUHG,QDGGLWLRQWKHTXDOLW\VFRUHVZHUHFDWHJRUL]HGLQWRJRRGñDQGSRRU
7KHNDSSDFRHI¿FLHQWZDVXVHGWRDVVHVVLQWHUUDWHUDJUHHPHQWIRUWKLVFDWHJRULFDOTXDOLW\VFRUHV
Results: A total number of 945 PolyIran participants were enrolled of which, 501 (53%) were from intervention arm. In 934 participants 
WKHTXDOLW\VFRUHFRXOGEHVXFFHVVIXOO\LGHQWL¿HGE\ERWKUDWHUV7KH,&&&,RIWKHRYHUDOOTXDOLW\VFRUHVZDV±
0.987). It was 0.976 (0.972–0.980) and 0.988 (0.986–0.990) in intervention and control arms, respectively. We found excellent agreement 
between the two raters in identifying participants with good and poor quality scores (kappa = 0.988, P < 0.001). The kappa values were 
0.972 (P < 0.001) and 1.000 (P < 0.001) in intervention and control arms, respectively.
Discussion: Our results suggested that the PIQCP questionnaire is a reliable tool for assessing quality of data collection in PolyIran 
IROORZXSYLVLWV8VLQJWKLVPHDVXUHZLOOKHOSXVLQHI¿FLHQWPRQLWRULQJRIWKH3RO\,UDQIROORZXSVDQGPD\HQVXUHKLJKTXDOLW\GDWD
Keywords: Follow-up visit, PolyIran study, quality control, reliability
Cite this article as: Roshandel G, Ostovaneh MR, Poustchi H, Malekzadeh F, Sepanlou SG, Honarvar MR, Semnani S, Merat S, Malekzadeh R. Reliability Analysis 
of a Newly Developed Questionnaire for Quality Control of Follow-up Visits in PolyIran Study. Arch Iran Med. 2016; 19(8): 551 – 555.
Original Article 
Reliability Analysis of a Newly Developed Questionnaire for 
Quality Control of Follow-up Visits in PolyIran Study
Gholamreza Roshandel MD PhD1,2, Mohammad Reza Ostovaneh MD2, Hossein Poustchi MD PhDƔ, Fatemeh Malekzadeh MD2, 
Sadaf Ghajarieh Sepanlou MD PhD2, Mohammad Reza Honarvar MD PhD3, Shahryar Semnani MD1, Shahin Merat MD2, 
Reza Malekzadeh MD2
$XWKRUV¶ DI¿OLDWLRQV 1Golestan Research Center of Gastroenterology and 
Hepatology, Golestan University of Medical Sciences, Gorgan, Iran. 2Digestive 
Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, 
Tehran University of Medical Sciences, Tehran, Iran. 3Department of Health, 
Golestan University of Medical Sciences, Gorgan, Iran.
•Corresponding author and reprints: Hossein Poustchi MD, Digestive Disease 
Research Center, Digestive Disease Research Institute, Tehran University 
of Medical Sciences, Shariati Hospital, 1411713135, Tehran, Iran. Telefax: 
+982182415104, E-mail. h.poustchi@gmail.com
Accepted for publication: 15 May 2016
Archives of Iranian Medicine, Volume 19, Number 8, August 2016552
Reliability of PolyIran Quality Control Program
the control group asking about the quality of data collection on all of 
the follow-up activities (Table 1). The questionnaires were completed 
by an experienced staff after reviewing the PolyIran follow-up data 
collection forms and by telephone interviews with followed up 
participants. A PIQCP guideline was also developed, in which the 
methods of scoring the quality of data were described in detail.
Because the PIQCP questionnaire was a new questionnaire 
developed for the PolyIran, we decided to validate this quality 
control measure. Validation studies mainly assess the validity 
and reliability of questionnaires. The different aspects of validity 
of the PIQCP questionnaire (content validity, face validity and 
construct validity) were assessed and approved by experts and 
H[SHULHQFHG LQGLYLGXDOV LQ WKLV ¿HOG ,Q WKH SUHVHQW VWXG\ ZH
aimed to determine the inter-rater reliability (agreement) for the 




This study was done on the PolyIran study participants during 
May and September 2015. A total of 8410 participants were 
enrolled in PolyIran study, including 4233 participants (120 
clusters) and 4177 (116 clusters) in the intervention and control 
arms, respectively.
Sample size
We aimed to enroll about 10% of the PolyIran participants (800 
participants) in this validation study with the intervention/control 
ratio of 1/1.
Sampling
Considering a median cluster size of about 30 participant,7 we 
aimed to enroll 26 PolyIran clusters to achieve a total sample size 
of about 800 for the present study. According to the timetable 
of the PolyIran follow-up, 180 clusters (90 clusters from the 
control and 90 clusters from the intervention arms) were followed 
between May and September 2015. Of these followed clusters, 13 
intervention and 13 control clusters were randomly selected for 
this validation study. We aimed to enroll all PolyIran participants 
within these cluster. 
Data collection
For all participants within selected clusters, the quality 
scores were assessed (using the PIQCP questionnaire) by two 
independent raters within one week after the end of follow-up. 
The quality scores were measured by the PIQCP questionnaire 
according to the PIQCP guidelines (Table 1). Thus, the following 
process was considered to measure the quality score for each 
participant.  
$W ¿UVW WKH TXDOLW\ VFRUH RI HDFK DFWLYLW\ DFWLYLW\VSHFL¿F
quality score) was calculated (Table 1). For each of the PolyIran 
follow-up activities, a maximum score was earned if the data were 
correctly and completely collected according to the protocol of 
the PolyIran follow-up and there was no error. Otherwise, part 
of the score was earned (based on the level of incompleteness, 
errors, etc). For example, according to the protocol of the PolyIran 
follow-up, the section of “demographic data” included 5 items 
¿UVWQDPHODVWQDPHSDUWLFLSDQWV,'YLOODJHFRGHGDWH6RLI
there was an error in one of these items, 80% of the maximum 
score would be earned for this activity, and so on. Then, the sum 
Activity 
code Activity details








A1 To record participants’ demographic data 10 10 SO (SO*100) / SE
A2 To calculate and record number of Polypill tablets have been taken/ had to be taken by participants 35 — SO (SO*100) / SE
A3 To record the reasons for non-adherence 15 — SO (SO*100) / SE
A4 To assess and record blood pressure 35 50 SO (SO*100) / SE
A5 To refer hypertensive participants to health system physician 15 25 SO (SO*100) / SE
A6 To obtain and record data on newly occurred cardiovascular events 15 25 SO (SO*100) / SE
A7 To record drug history (Aspirin, Anti-lipid, Anti-hypertensive) — 25 SO (SO*100) / SE
A8 To record new symptoms 30 40 SO (SO*100) / SE
A9 To record the participant’s follow-up status and reasons for loss to follow up 10 25 SO (SO*100) / SE
A10 7RPDNHDQGUHFRUG¿QDOGHFLVLRQRQGUXJFRQWLQXDWLRQfor the next 6 months 20 — SO (SO*100) / SE
A11 To refer participants with adverse events (or any other problems) for physician visit 35 35 SO (SO*100) / SE
A12 To give the Polypill tablets to participants 35 — SO (SO*100) / SE
A13 To prepare the list of participants needed to be visited by the study physician 15 15 SO (SO*100) / SE
A14 To give the participants information on lifestyle PRGL¿FDWLRQ 30 50 SO (SO*100) / SE
Overall quality score 6E=300 6E=300 6O 6O6E
Table 1. &DOFXODWLQJDFWLYLW\VSHFL¿FDQGRYHUDOOTXDOLW\VFRUHVIRUHDFKSDUWLFLSDQWLQWKH3RO\,UDQ4XDOLW\&RQWURO3URJUDP3,4&3
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of scores of all activities (overall observed score) was calculated. 
Finally, the “overall quality score” was calculated by dividing 
the “overall observed score” by sum of maximum scores of 
all activities (overall expected score) (Table 1). Each rater was 
blinded to the results reported by the other.
Analysis of data
7KHDFWLYLW\VSHFL¿FTXDOLW\VFRUHVDVZHOODVWKHRYHUDOOTXDOLW\
score were calculated for each participant using the above-
PHQWLRQHGIRUPXOD7DEOH7KHLQWUDFODVVFRUUHODWLRQFRHI¿FLHQW
,&& DQG LWV FRQ¿GHQFH LQWHUYDOV &,ZHUHPHDVXUHG WR
assess the level of agreement between the raters. Bland-Altman 
graph10 was also used to assess the concordance of quality scores 
reported by rater 1 and rater 2.
In addition, the quality of data collection was categorized as 
good (quality score ³ 70%) or poor (quality score < 70%). The 
NDSSD FRHI¿FLHQW ZDV XVHG WR DVVHVV LQWHUUDWHU DJUHHPHQW IRU
this categorical quality scores. P values of less than 0.05 were 
FRQVLGHUHGVLJQL¿FDQW
Results
A total of 945 PolyIran participants were enrolled, of which, 472 
(49.9%) were male and the mean (SD) age of participants was 
60.01 (7.14) years. A total of 501 participants (53%) were recruited 
from the intervention arm. The number of male participants in the 
intervention and control arms was 246 (49.1%) and 226 (50.9%), 
respectively (P value = 0.58). The mean (SD) of participants’ age 
was 59.88 (7.21) and 60.27 (7.07) years in the intervention and 
control arms, respectively (P value = 0.40). 
In 934 participants (98.8%), the quality score could be 
VXFFHVVIXOO\LGHQWL¿HGE\ERWKUDWHUV7KHPHDQ6'RIRYHUDOO
quality scores reported by raters 1 and 2 was 94.8% (13.9) and 
95.1% (14.3), respectively. Table 2 shows the means of the overall 
quality scores in the intervention and control arms.
The quality of data was rated as good in 95.1% and 95.2% 
of participants by raters 1 and 2, respectively. The number 
(proportion) of participants with good and poor quality scores 
reported by raters 1 and 2 in the intervention and control arms is 
shown in Table 2.
The ICC (95% CI) of the overall quality scores reported by 
raters 1 and 2 was 0.985 (0.983–0.987). The ICCs (95% CI) of the 
overall quality scores in the intervention and control arms were 
0.976 (0.972–0.980) and 0.988 (0.986–0.990), respectively. Table 
 VKRZV WKH ,&&V &,V RI DFWLYLW\VSHFL¿F TXDOLW\ VFRUHV
reported by the two raters in the intervention and control arms. 
Figure 1 shows the concordance of two raters in assessing 
quality scores in PolyIran participants.
Our results showed an excellent agreement between the two 
raters in identifying participants with good and poor quality 
scores (kappa = 0.988, P < 0.001). The kappa values were 0.972 
(P < 0.001) and 1.000 (P < 0.001) in the intervention and control 
arms, respectively.
Discussion
The PolyIran study is a large-scale pragmatic randomized 
controlled trial.7 It was conducted at the community level and 
large number of healthcare workers (behvarzes) were involved in 
the process of data collection and follow-up. It was believed that 
follow-up visits were an important phase of the PolyIran study 
and quality of data collection in this phase could strongly affect 
the study results. To ensure high-quality data acquisition and 
reporting during PolyIran follow-up visits, a quality assurance 
and monitoring program (PIQCP) was designed for the PolyIran 
VWXG\$QHZ3,4&3VSHFL¿FTXHVWLRQQDLUHZDVGHYHORSHG DQG
the quality of data collection was regularly assessed according to 
the PIQCP guideline during each round of follow-up. The PIQCP 
questionnaire was a newly developed questionnaire and needed 
to be validated in the study population. The aim of this study was 
to assess the inter-rater reliability of PIQCP questionnaire in the 
PolyIran study.
2XU¿QGLQJVVXJJHVWHGKLJKLQWHUUDWHUUHOLDELOLW\YDOXHVIRUWKH
PIQCP questionnaire. Both quantitative and qualitative analyses 
showed high concordance for assessing the overall quality scores 
between the two raters (Table 2 and Figure 1). In addition, table 3 
VKRZVKLJK,&&VIRUDOODFWLYLW\VSHFL¿FTXDOLW\VFRUHV7KHUHIRUH
the PIQCP questionnaire was a reliable tool for assessing quality 
of data collection in PolyIran follow-up visits.
The effects of polypill strategy have been studied on CVD 
outcomes in different populations.11–15 But, similar to many other 
researches,16 little information was reported on measures of 
quality control and quality assurance for follow-up data collection 
in these studies. Quality control is one of the most important issues 
of clinical trials, especially those with large number of study sites 
and many different interviewers.17 Data of poor quality may have 
strong negative effects on the power of study18,19. Many different 
factors may affect the quality of data in clinical researches, 
including study design, sample size, complexity of data collection, 
etc. Therefore, different methods may be considered to ensure 
high quality data in various studies.20,21 In addition, an individual 
study may need different quality control measures during each 
phase of the study. Marinez et al. considered an integrated data 
management system to ensure high quality data.22 In a study 
Statistics Raters Intervention arm(n = 492)
Control arm
(n = 442) P-Value
Mean (SD) of quality score
Rater 1 95.7 (10.3) 93.8 (15.1) 0.06
Rater 2 95.9 (10.2) 94.3 (15.7) 0.09
Number (%) of participants with good 
and poor  quality scores
Rater 1
Good  quality 473 (96.1) 415 (93.9)
0.11
Poor quality 19 (3.9) 27 (6.1)
Rater 2
Good  quality 474 (96.3) 415 (93.9)
0.08
Poor quality 18 (3.7) 27 (6.1)
Table 2. The mean (SD) of the overall quality scores as well as the number (proportion) of participants with good (quality score t 70%) and poor 
(quality score<70%) quality scores reported by raters 1 and 2 in intervention and control arms of the PolyIran study.
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from Malawi, using a local quality assessment tool could result 
in improvements in data quality.23,24 In the Diabetes Control and 
Complications Trial and the follow-up Epidemiology of Diabetes 
Interventions and Complications study a quality assurance 
program was implemented to identify trends, data inconsistencies 
and process variability of results over time.17 Therefore, it is 
important to design and implement an appropriate quality control 
program for different  phases of clinical researches, especially 
large-scale clinical trial.18,25 
In conclusion, we found high inter-rater accordance for 
DVVHVVLQJ WKH RYHUDOO DQG DFWLYLW\VSHFL¿F TXDOLW\ VFRUHV 2XU
results suggested that the PIQCP questionnaire is a reliable tool 
for assessing quality of data collection in PolyIran follow-up 
YLVLWV8VLQJWKLVPHDVXUHZLOOKHOSXVLQHI¿FLHQWPRQLWRULQJRI
the PolyIran follow-ups and will consequently ensure high quality 
data in this large-scale pragmatic randomized controlled trial.
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Activity 
code Activity details Intervention arm, ICC (95%CI)
Control arm,
ICC (95%CI)
A1 To record participants’ demographic data 0.772 (0.727–.0809) 0.822 (0.806–0.836)
A2 To calculate and record number of Polypill tablets have been taken/ had to be taken by participants 0.874 (0.843–919) N/A
A3 To record the reasons for non-adherence 0.969 (0.963–0.974) N/A
A4 To assess and record blood pressure 0.864 (0.838–0.868) 0.907 (0.888–0.923)
A5 To refer hypertensive participants to health system physician 0.962 (0.954 – 0.968) 0.972 (0.966–0.977)
A6 To obtain and record data on newly occurred cardiovascular events 0.953 (0.944–0.960) 0.996 (0.995–0.996)
A7 To record drug history (Aspirin, Anti-lipid, Anti-hypertensive) N/A 0.959 (0.951–0.966)
A8 To record new symptoms 0.960 (0.952–0.966) 0.995 (0.994–0.996)
A9 To record the participant’s follow-up status and reasons for loss to follow up 0.986 (0.983–0.988) 0.981 (0.977–0.984)
A10 7RPDNHDQGUHFRUG¿QDOGHFLVLRQRQGUXJFRQWLQXDWLRQIRUWKHnext 6 months 0.918 (0.902–0.932) N/A
A11 To refer participants with adverse events (or any other problems) for physician visit 0.931 (0.917–0.942) 0.971 (0.965–0.976)
A12 To give the Polypill tablets to participants 0.900 (0.853–0.933) N/A
A13 To prepare the list of participants needed to be visited by the study physician 0.795 (0.698–0.861) 0.823 (0.743–0.879)
A14 7RJLYHWKHSDUWLFLSDQWVLQIRUPDWLRQRQOLIHVW\OHPRGL¿FDWLRQ 0.873 (0.813–0.914) 0.855 (0.745–0.932)
,&& LQWUDFODVVFRUUHODWLRQFRHI¿FLHQW1$ QRWDSSOLFDEOH
Table 3. The levels of agreement between raters 1 and 2 for assessing the quality scores for each activity of the PolyIran quality control program 
in intervention and control arms. 
Figure 1. Bland-Altman graph for assessing the concordance of two raters for measuring quality of data in PolyIran follow-up visits.
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